Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORION-PLAQUE inclisiran CCTA plaque progression study in non-obstructive CAD
jRCT2071230017Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis, non-obstructive coronary artery disease and hypercholesterolemia comparing Inclisiran arm with Placebo arm (2 arms). Primary endpoint: Percentage change in total coronary atheroma volume. Started Jun 2023; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
coronary arteriosclerosisnon-obstructive coronary artery diseasehypercholesterolemia
Beyond the preview
Go deeper on jRCT2071230017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230017.